References for A Confounding Condition

Vol. 4 • Issue 4 • Page 37

1. Ehrlich GE. Pain Is Real; Fibromyalgia Isn't. J Rheumatol. 2003 Aug;30(8):1666-7.

2. Wolfe F. Stop Using the American College of Rheumatology Criteria in the Clinic. J Rheumatol 200;30:8:1671-2.

3. Smythe H. Fibromyalgia Among Friends. J Rheumatol. 2004 Apr;31(4):627-30.

4. Holtorf K. Diagnosis and Treatment of Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysfunctionin Patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM). J Chronic Fatigue Syndrome 2008;14(3):59-88.

5. Riedel W, Layka H, Neeck. Secretory pattern of GH, TSH, thryoid hormones, ACTH, cortil, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998;57:81-87.

6. Neeck G, Riedel. Thyroid Function in Patients with Fibromy­algia Syndrome. J Rheumatology 1992;19(7):1120-1122.

7. Neeck G, Riedel W. Hormonal Perturbations in Fibromyalgia Syndrome. Annals New York Academy of Sciences 1999;876:325-339.

8. Simons DG, Travell JG. Myofacial pain syndromes, per­petuation factors. In Textbook of Pain. P.D. Wall & R. Malzak, Eds.1989:369-385.

9. McCain GA, Tilbe AK. Diurnal hormone variation in fibro­myalgia syndrome: A comparison with rheumatoid arthritis. J Rheumatol 1989;16(Supp19):154-157.

10. Ferraccioli G, Cavalieri F, Salaffi F, Fontana S, Scita F, Nolli M, Maestri D. Neuroendocrinologic findings in primary fi­bromyalgia and in other rheumatic conditions. J. Rheumatol 1990;17:869-873.

11. Englebienne P, Verhas M, Herst CV, Ke Meirleir K. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue. Med Hypoth 2003;60(2):175-180.

12. Garrison RL, Breeding PC. A metabolic basis for fibromy­algia and its related disorders: the possible role of resistance to thyroid hormone. Medical Hypoth 2003;61(2):182-189.

13. Cullum ME et al. Mutations in the c-erbAB1 gene: do they un­derlie euthyroid fibromyalgia. Medical Hypotheses 1997;48:125-135.

14. Lowe JC. Thyroid status of 38 Fibromyalgia Patients: Implica­tions for the Etiology of Fibromyalgia. Clin Bulletin Myofascial Therapy 1997;2(1):47-64.

15. Lowe JC, Reichman AJ, Honeyman GS, Yellin J. Thyroid Sta­tus of Fibromyalgia Patients. Clin Bulletin Myofascial Therapy 1998;3(1):69-70.

16. Lowe JC. The Metabolic Treatment of Fibromyalgia. Ed Yelin JC. McDowell Publishing Company 2000.

17. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with fibromyalgia syndrome. A possible link between sleep and muscle pain. Arthritis and Rheumatism 1992;35(10):1113-1110.

18. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM: Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J.Rheumatol. 1997; 24:1384-1389.

19. Bennett R. Growth Hormone in Musculoskeletal Pain States. Current Pain and Headache Reports 2005;9:331-338.

20. Bennett RM. Disordered growth hormone secretion in fibro­myalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol 1998;57(Supp 2):72-6.

21. Bennett RM, Clark SR, Walczyk J: A randomized, double-blind, placebo-controlled study of growth hormone in the treat­ment of fibromyalgia. Am J Med 1998;104:227-231.

22. Behen WH, More IR, Behan PO. Mitochondrial abnormali­ties in postviral fatigue syndrome. Acta Neuropathol 1991;83:61-65.

23. Pillemer S, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The Neuroscience and Endocrinology of FMS-[An NIH] Conference Summary. Arthritis & Rheumatism 1997;40 (11):1928-1939.

24. Drewes AM, Nielson KD, Taagholt SJ, Bjerregaard K, Svendson L, Gade J. Slow Wave Sleep in FMS. J. Musculoskeletal Pain 1995;3(Supp1):29.

25. Scharf MB, Baumann M, Berkowitz D. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with Fibromyalgia. J. Rheumatology 2003;30:1070-4.

26. Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986;81:85-9.

27. Moldofsky H. Sleep and fibrositis syndrome. Rheum Dis Clin North Am 1989;15:91-103.

28. Moldofsky H. The contribution of sleep-wake physiology to fibromyalgia. Adv Pain Res Ther 1990;17:227-240.

29. Klimas NG et al. Immunologic Abnormalities in Chronic Fa­tigue Syndrome J Clin Microbiology 1990;28(6):1403-1410.

30. Peterson, A. L. Komaroff, and J. Ritz. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J. Immunol 1987;139:3306-3313.

31. Fletcher MA, Maher KJ, Klimas NG. Natural killer cell function in chronic fatigue syndrome 2002;2(2):129-139.

32. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994;18(Supp 1):S157-9.

33. Komaroff A. The biology of Chronic Fatigue Syndorme. Am. J Med 2000;108:169-71.

34. Suhadolnik RJ et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I) poly(C12U) in chronic fatigue syndrome. In Vivo. 1994;8:599-604.

35. Suhadolnik RJ et al. Upregulation of the 2-5A synthetase/ RNase L antiviral pathway associated with chronic fatigue syn­drome. Clin Infect Dis 1994;18:S96-S104.

36. Suhadolnik RJ et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon & Cytokine Res1997;17:377-85.

37. Suhadolnik RJ et al. Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome. J Chronic Fatigue Syndrome.1999;5:223-242.

38. De Meirleir K et al. A 37 kDa 2-5A binding protein as a po­tential biochemical marker for chronic fatigue syndrome. Am J Med 2000;108(2):99-105.

39. Zorenzenon M, Rukh G Botta GA et al. Active HHV-6 infec­tion in chronic fatigue syndrome patients from Italy: New data. J Chron Fatigue Syndrome 1996;2(4):3-12.

40. Jo Nijs J et al. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Exami­nation of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunology & Medical Microbiology 2002;34: 209-214.

41. Nicolson G, Nicolson N. Diagnosis and treatment of Myco­plasmal Infections in Persian Gulf War Illness-CFIDS Patients. International Journal of Occupational Medicine, Immunology and Toxicology 1996;5:69-78.

42. Knox KK, Brewer JH, and Carrigan DR. Persistent active hu­man herpesvirus six (HHV-6) infections in patients with chronic fatigue syndrome. J Chronic Fatigue Syndrome 1999;5:245-246.

43. Brewer JH, Know KK and Carrigan DR. Longitudinal study of chronic active human herpesvirus 6 (HHV-6) viremia in pa­tients with chronic fatigue syndrome. Abstract. IDSA 37th An­nual Meeting. Nov. 18-21, 1999. Philadelphia, Pennsylvania 

44. Ablashi DV et al. Human herpes virus and chronic fatigue syndrome. Canad Dis Weekly Rep 1991;17S1:33-40.

45. Josephs SF et al HHV-6 reactivation in chronic fatigue syn­drome. Lancet 1991;1346-7.

46. Nicolson GL, Gan R, Haier J. Multiple co-infections (Myco­plasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS 2003;111(5):557-66.

47. Buchwald D. et al. A Chronic Illness Characterized by Fa­tigue, Neurological and Immunological Disorders, and Active Human Herpesvirus Type 6 Infection. Annals of Internal Medi­cine 1992;116:103-113.

48. Martin W.J. Detection of viral related sequences in CFS pa­tients using the polymerase chain reaction.in "The Clinical and Scientific Basis of Myalgic Encephalomyelitis Chronic Fatigue Syndrome." Byron M. Hyde Editor. Nightingale Research Foun­dation Press. Ottawa Canada pp 278-283, 1992.

49. Rowe PC, Bou-Holaigah I, Kan JS, Calkins H. Is NMH an Un­recognized Cause of Chronic Fatigue? Lancet 1995;345:623-4.

50. Naschitz JE, Rosner I, Rozenboum M et al. The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome. QJ Med 2003;96:133-142.

51.Gerrity TR, Bates J, Bell DS, Chrousos G, Furst G, Hedric T, Hurwitz B, Kula RW, Levine SM, Moore RC, Schondorf R. Chronic fatigue syndrome: what role does the autonomic ner­vous system play in the pathophysiology of this complex illness? NeuroImmunoModulation 2002;10:134-141.

52. Wallace DJ, Gallegua DS. Fibromyalgia: The Gastrointesti­nal Link. Current Pain and Headache Reports 2004;8:364-368.

53. Sivri A; Cindas A; Dincer F; Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Clin Rheuma­tol 1996;15(3):283-6.

54. Triadafilopoulos G; Simms RW; Goldenberg DL. Bowel dys­function in fibromyalgia syndrome. Dig Dis Sci 1991;36(1):59-64.

55. M Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath test­ing. Annals of the Rheumatic Diseases 2004;63:450-452.

56. Mark Pimentel et al.,Small Intestinal Bacterial Overgrowth: A Possible Association with Fibromyalgia, Journal of Musculo­skeletal Pain 2001;9(3):107-113.

57. Berg D, Berg LH, Couvaras J, Harrison H. Chronic Fatigue Syndrome (CFS) &/or Fibromyalgia (FM) as a Variation of An­tiphospholipid Antibody Syndrome (APS): An Explanatory Model and Approach to Laboratory Diagnosis of Blood Coagu­lation and Fibrinolysis 1999;10:1-4.

58. Berg D, Berg LH, Couvaras J. Is CFS/FM due to an unde­fined Hypercoaguable state brought on by immune activation of coagulation. Does adding anticoagulant therapy improve CFS/FM patient symptoms? AACFS Proceedings, Cambridge, MA, 10-12 October1998:62.

59. Berg D, Berg LH, Harrison H, Dreschsel. Retrospective study of 400+ CFS/FM patients for immune system activation of coagulation and hereditary coagulation defects as predisposi­tion for CFS/FM. Proceedings International Society Thrombosis & Hemostasis July, 2001.

60. Harrison H, Ryser CA, , Brewer J, Berg D. Procoagulant Ge­netic Factors in a Pooled Cohort of 582 Chronic Fatigue Syn­drome, Fibromyalgia and Related Chronic Illness Cases. VIIth International Conference American Association for Chronic Fa­tigue Syndrome (AACFS), Oct, 2004, Madison, WI, USA

61. Berg D, Berg LH, Harrison H. Low Level Activation of Co­agulation with Coagulopathies in the Etiology of CFS / FM and Chronic Illnesses. An Explanatory Model Revisited. VIIth Inter­national Conference, American Association for Chronic Fatigue Syndrome (AACFS) Meeting, Madison, WI, Oct, 2004.

62. Harrison HH, Ryser CA, Ryser ME, et al. Use of sensitive markers of coagulation activation to monitor low dose hepa­rin therapy in patients with CFS and FM. Clinical Chemistry 2003;49(S6):A9.

63. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994 Jan;18 Suppl 1:S157-9.

64. Gin W, Christiansen FT, Peter JB. Immune function and chronic fatigue syndrome. Med J Aust 1989:151:117-8.

65. Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987:139:3306-13.

66. Stricker RB, Winger EE. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. Immunol Lett. 2001 Feb 1;76(1):43-8.

67. Klimas N, Salvato F, Morgan R, Fletcher M. Immunologic Abnormalities in Chronic Fatigue Syndrome. Journal of Clinical Microbiology, June 1990:1403-10.

68. Suhadolnik RJ et al. Biochemical evidence for a novel low mole-cular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon & Cytokine Res.1997;17:377-85.

69. Suhadolnik RJ et al. Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome. J Chronic Fatigue Syndrome.1999;5:223-242.

70. De Meirleir K et al. A  37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med.2000;108(2):99-105.

71. Suhadolnik RJ et al. Diagnosis of chronic fatigue syndrome (CFS): determination of a low molecular weight 37 kDa 2-5A dependent RNase L in peripheral blood mono-nuclear cell extracts. Second World Congress on Chronic Fatigue Syndrome and Related Disorders, Brussels, September 9-12, 1999.

72. Teitelbaum J, Bird B, Greenfield R, Weiss A, Muenz L, Gould L. Effective Treatment of Chronic Fatigue Syndrome (CFIDS) & Fibromyalgia (FMS) - A Randomized, Double-Blind, Placebo-Controlled, Intent To Treat Study. Journal of Chronic Fatigue Syndrome 2001;8(2):3-28.

73. Blatman H. Effective Treatment of Fibromyalgia and Myo­fascial Pain Syndrome: A Clinician's Perspective. American Jour­nal of Pain Management (Journal of the American Academy of Pain Management) 2002;12(2):67-68.

74. Teitelbaum J. Effective Treatment of Chronic Fatigue Syn­drome: Clinical Protocols and Practice. Integrative Medicine 2005;4(4):CD-CG.

75. De Meirleir K, Englebienne P. Chronic Fatigue Syndrome: A Biological Approach. CRC Press. 2002.

76. International Association for Chronic Fatigue Syndrome (IACFS), Centers for Disease Control and Prevention (CDC) and the National Center for Infectious Diseases. Seventh Inter­national Conference on Chronic Fatigue Syndrome, Fibromyal­gia and Other Related Illnesses. October 8-10, Madison, Wis­consin 2004.

77. International Association for Chronic Fatigue Syndrome (IACFS), Centers for Disease Control and Prevention (CDC) and PANDORA. Eighth International Conference on Chronic Fatigue Syndrome, Fibromyalgia and Other Related Illnesses. Fort Lauderdale, FL Jan 12-14, 2007.

78. Latest 21st Century Advances in the Diagnosis & Treatment of Fibromyalgia, Chronic Fatigue Syndrome and Related Illness­es. Los Angeles, CA Sept 19-21, 2002.

79. Ali M et al. Efficacy of ecologic-integrative management; protocols for reversal of fibromyalgia. J Integrative Medicine 1999;3:48-64.

80. Lowe JC, Reichman AJ, Yellin J. The process of change dur­ing T3 treatment for euthyroid fibromyalgia: a double-blind pla­cebo-controlled crossover Study: Clinical Bulletin of Myofascial Therapy 1997;2(2/3):91-124.

81. PreAmerican Association for CFS/FMS 7th International Conference. A clinically focused workshop on Effective CFS/Fi­bromyalgia Therapies. October 7, 2004 Madison, Wisconsin.

82. Potential Unique etiologies of Chronic Fatigue Syndrome and Fibromyalgia: Hypercoaguable State, Neurotoxins & Heavy Metals. Fifth Annual Fibromyalgia and Chronic Fatigue Con­ference. Kansas City, MO. Fibromyalgia Coalition International May 14, 2005.

83. Hormone Replacement Therapy in the Treatment of Fibro­myalgia and CFIDS/Fibromyalgia CME Conference National Fi­bromyalgia Association. Garden Grove, CA. May 18, 2006.

84. The Treatment of the Metabolic Consequences of CFS/FM and Chronic Infections. American College for the Advancement of Medicine. Dallas, TX. May 4, 2006.

85. Teitelbaum J. From Fatigue to Fantastic. Penguin Putnam Inc, 2001.

86. Holtorf K, Wightman W, Tenenbaum S, Shah P, White MD. Outcome database of 500+ CFS/FM patients. Holtorf Medical Group Inc, Center for Hormone Imbalance, Hypothyroidismand Fatigue, Torrance, CA 2007.

87. Holtorf K, Wightman W, Tenenbaum S, Shah P, White MD, Spurlock M, Kippels K, LaBair A, Sharp L, Pierotti A, Bullington K, Garcia A, Stevens J, Sainer D, Campo A, Garabedian A, Marti L, Taveau S, Cuddapah S, Mustafa S, Stringer B, Boulden K, Bial E, Truong B, Elzinga L, Wazni G, Whitaker J, Cuddapah S, Lip­schutz S, Stringer DiGiovanni M, Levitz L, Hamp D, Juguilon F, Calabrese D, Zahoor I, Nurse-Bey H, Sidhwa Y, Shanti I, Littles C, Kelly L. Outcome database of 5000+ CFS/FM patients. Dallas TX, Fort Worth TX, Las Vegas NV, Salt Lake City UT, Portland OR, Seattle WA, Atlanta GA, Norwalk CT, Boston MA, Philadel­phia PA, Cleveland OH, Denver CO, Houston, TX, Detroit MI, Pittsburgh PA, Amarillo TX, Houston TX.

88. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990;33:160---72.

89. Katz RS, Wolfe F,2 Michaud K. Fibromyalgia Diagnosis: A Comparison of Clinical, Survey, and American College of Rheumatology Criteria. Arthritis & Rheumatism Vol. 54, No. 1, January 2006, pp 169-176

90. Wolfe F. Diagnosis of fibromyalgia. J Musculoskel Med 1990;7:53-69.

91. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003;17:563-74.

92. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia:What we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701.

93. Crofford LJ, Clauw DJ. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? [editorial]. Arthritis Rheum 2002;46:1136-8.

94. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, Evengard B, White PD, Nisenbaum R, Unger ER, and the International Chronic Fatigue Syndrome Study Group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Services Research 2003;3:25. 

95. Wearden AJ, Morriss RK, Mullis R, et al. Randomized, double-blind, placebo-controlled treatment trial of fluoxetine and grad­ed exercise for chronic fatigue syndrome [published erratum appears in Br J Psychiatry 1998;173:89]. Br J Psychiatry 1998. 172:485-90.

96. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. The Lancet 1996;347:858-61.  

97. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Gold­enberg DL, Russell IJ, Yunus MB. Health status and disease se­verity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997 Sep;40(9):1571-9.

98. Andersen MM, Permin H, Albrecht F. Illness and disabil­ity in Danish Chronic Fatigue Syndrome patients at diagno­sis and 5-year follow-up. Journal of Psychosomatic Research 2004;56:217-229.

99. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue syndrome: a systematic review. Q J Med 1997;90(3):223-33.

100. Hoffman C, D. Rice D, Sung HY. Persons with chronic condi­tions. Their prevalence and costs. JAMA. Vol. 276 No. 18, No­vember 13, 1996.

101. Levine PH et al. The Postinfectious Chronic Fatigue Syn­drome. Humana Press, Clifton NJ 1989:405-38.

102. Deale A, Wessely S. Patients' perceptions of medical care in chronic fatigue syndrome. Social Science & Medicine 2001;52:1859-1864.

103. Hinds GME, McCluskey DR. A retrospective study of chron­ic fatigue syndrome. Proc Roy Coll Physicians, Edinburgh 1993; 23:10-14.

104. Peterson PK, Schenck CH, Sherman R. Chronic fatigue syn­drome in Minnesota. Minnesota Medicine 1991;74:21-6. Pain 1995;3:91-110.

105. Bennett RM: Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum 1996;39:1627-1634.

106. Kennedy M, Felson DT. A prospective long-term study of fi­bromyalgia syndrome. Arthritis Rheum. 1996;39(4):682-5.

107. Wilson A et al. The treatment of chronic fatigue syndrome: science and speculation. Am J Med 1994;96(6):544-50. 

108. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15.

109. Barclay L, Vega C. Duloxetine Effective in Fibromyalgia. Med­scape Medical News. Sept 10, 2004.

110. Crofford LJ, Rowbotham MC, Mease PJ, Russell J, SworkinRH, et al. Pregabalin for the treatment of fibromyalgia. Arthritis and Rheumatism 2005;52(4):1264-1273.

111. Nicolson G, Ellithorpe R. Lipid Replacement and Antioxi­dant Nutritional Therapy for Restoring Mitochondrial Func­tion and Reducing Fatigue in Chronic Fatigue Syndrome and other Fatiguing Illnesses. Journal of Chronic Fatigue Syndrome 2006;13(1):57-68.

112. Gebhart B. Benefit of Ribose in a Patient with Fibromyalgia. Pharmacotherapy 2004;24(11):1646-1648)

113. Rossini M, Di Munno O, valentine G, Bianchi G, Biasi G, et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 2007;25(2): 182-8.

114. Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. Altern Complement Med. 2006 Nov;12(9):857-62.

115. Massey PB. Reduction of fibromyalgia symptoms through intravenous nutrient therapy: results of a pilot clinical trial. Altern Ther Health Med. 2007;13(3):32-4.

116. Cox I. Red blood cell magnesium and chronic fatigue syndrome .  The Lancet 1991;8744:757 - 760.

117. Rose SR; Lustig RH; Pitukcheewanont P; Broome DC; Burghen GA; Li H; Hudson MM; Kun LE. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999;84(12):4472-9.

118. Robin P. Peeters, Pieter J. Wouters, Hans van Toor, Ellen Kaptein, Theo J. Visser, and Greet Van den Berghe. Serum 3,3_,5_-Triiodothyronine (rT3) and 3,5,3_-Triiodothyronine/rT3 Are Prognostic Markers in Critically Ill Patients and Are Associated with Postmortem Tissue Deiodinase Activities. The Journal of Clinical Endocrinology & Metabolism 90(8):4559-4565.

119. Annewieke W. van den Beld, Theo J. Visser, Richard A. Feelders, Diederick E. Grobbee, and Steven W. J. Lamberts Thyroid Hormone Concentrations, Disease, Physical Function, and Mortality in Elderly Men. J Clin Endocrinol Metab 2005;90: 6403-6409.

120. Robin P. Peeters, Serge van der Geyten, Pieter J. Wouters, Veerle M. Darras, Hans van Toor, Ellen Kaptein, Theo J. Visser, and Greet Van den Berghe. Tissue Thyroid Hormone Levels in Critical Illness. J Clin Endocrinol Metab 2005;90:6498-6507.

121. Lowe J, Garrison R, Reichman A, MD, Yellin J, Thompson BA, Kaufman D. Effectiveness and safety of T3 (triiodothyro­nine) therapy for euthyroid fibromyalgia: a double-blind place­bo-controlled response-driven crossover study.: Clinical Bulletin of Myofascial Therapy 1997;2(2/3):31-58.

122. Lowe JC, Reichman AJ, Garrison R, Yellin J.. Triiodothyro­nine (T3) treatment of euthyroid fibromyalgia: a small-n replica­tion of a double-blind placebo-controlled crossover study. Clini­cal Bulletin of Myofascial Therapy 1997;2(4):71-88.

123. Yellin BA, Reichman AJ, Lowe JC. The Process of Change During T3 Treatment for Euthyroid Fibromyalgia: A Double-Blind Placebo-Controlled Crossover Study. The Metabolic Treat­ment of Fibromyalgia. McDowell Publishing 2000.

124. Moorkens G, Wynants H, Abs R: Effect of growth hormone treatment in patients with chronic fatigue syndrome: a prelimi­nary study. Growth Horm IGF Res 1998;8(B):131-133.

125. Nicolson, G, Marwan Y. Nasralla M, De Meirleir K, J Haier. Bacterial and Viral Co-Infections in Chronic Fatigue Syndrome (CFS/ME) Patients. Proc. Clinical & Scientific Conference on Myalgic Encephalopathy/Chronic Fatigue Syndrome, the Practi­tioners Challenge, Alison Hunter Foundation, Sydney, Australia 2002.

126. Lerner AM, Zervos M and Chang CH et al. A small, ran­domized, placebo-controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. Clinical Infectious Diseases 2001;32:1657-58.

127. Nicolson, G. L., Nasralla, M. Y. , Franco, R, A., Nicolson, N. L., Erwin, R., Ngwenya, R. &, and Berns, P.A. Clinical Practice of Alternative Medicine 2000;1(2):92-102.

128. Montoya et al. Use of valganciclovir (Valcyte) in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fa­tigue. Journal of Clinical Virology 2006;37:S33-38.

129. Shoemaker, R. C., Hudnell, H. K. 2001, "Possible Estuary Associated Syndrome: symptoms, vision and treatment", Environmental Health Perspectives ; 109(5): 539-545.

130. Shoemaker, R. C. 2000, "Poster H05, Treatment of Possible Estuarine Associated syndrome: Neurotoxins, contrast sensitivity and cholestyramine", CDC National Conference on Pfiesteria: From Biology to Public Health 10/18-10/20/2000, Stone Mountain, Georgia.

131. Shoemaker RC. Residential and recreational acquisition of Possible Estuary Associated Syndrome: a new approach to successful diagnosis and treatment, Environmental Health Perspectives 2001;109(S5): 791-796.